GoodRx (NASDAQ:GDRX) Posts Quarterly Earnings Results, Meets Expectations

GoodRx (NASDAQ:GDRX) issued its earnings results on Wednesday, February 25th. The company reported $0.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.09, FiscalAI reports. The firm had revenue of $194.79 million for the quarter, compared to analyst estimates of $193.27 million. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The company’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the business posted $0.09 earnings per share.

GoodRx Stock Performance

NASDAQ GDRX opened at $2.05 on Monday. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.61 and a quick ratio of 2.61. The company has a fifty day moving average price of $2.21 and a 200-day moving average price of $2.88. GoodRx has a 1 year low of $1.77 and a 1 year high of $5.81. The firm has a market cap of $702.27 million, a price-to-earnings ratio of 22.78, a PEG ratio of 1.42 and a beta of 1.47.

Analysts Set New Price Targets

GDRX has been the subject of several analyst reports. Leerink Partners reaffirmed an “outperform” rating and set a $3.00 price target on shares of GoodRx in a research note on Thursday, February 26th. Jefferies Financial Group cut shares of GoodRx to a “hold” rating in a research report on Thursday, January 22nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GoodRx in a research report on Friday, February 27th. Bank of America reissued a “reduce” rating on shares of GoodRx in a research note on Monday, January 5th. Finally, Wall Street Zen lowered shares of GoodRx from a “buy” rating to a “hold” rating in a research note on Sunday, January 25th. Five analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.98.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Virtu Financial LLC raised its position in GoodRx by 903.3% in the fourth quarter. Virtu Financial LLC now owns 133,886 shares of the company’s stock worth $363,000 after acquiring an additional 120,542 shares during the period. Invesco Ltd. raised its stake in GoodRx by 48.8% in the 4th quarter. Invesco Ltd. now owns 186,534 shares of the company’s stock valued at $506,000 after acquiring an additional 61,193 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in GoodRx during the fourth quarter worth about $51,000. EP Wealth Advisors LLC purchased a new stake in shares of GoodRx during the 4th quarter valued at approximately $44,000. Finally, Mackenzie Financial Corp purchased a new position in GoodRx in the 4th quarter valued at approximately $1,009,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.